After Hours
$
22.50
Change
+0.08 +0.36%
Volume
Volume 9,860
Jan 27, 2023, 7:59 p.m.
Quotes are delayed by 20 min
Previous close
$ 22.01
$ 22.42
Change
+0.41 +1.86%
Day low
Day high
$21.78
$22.92

52 week low
52 week high
$10.70
$43.00

Market cap
$1.38B
Average volume
825,559
P/E ratio
N/A
Rev. per Employee
$8,221
EPS
-2.90
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on VERV
-
What’s Next for the Healthcare Industry, and How to Invest
- Barron's Online
-
Verve Therapeutics stock upgraded to buy from hold at Stifel
- Emily Bary
-
Verve Therapeutics price target increased to $56 from $32 at Stifel
- Emily Bary
-
25 Stocks That Could Rise on a Short Squeeze
- Barron's Online
-
Canoo and 4 More EV Stocks Are at Risk of a 'Short Squeeze.' Beware.
- Barron's Online
-
Verve Therapeutics started at outperform with $48 stock price target at BMO Capital
- Tomi Kilgore
-
Verve Therapeutics reiterated as hold with $58 stock price target at Stifel
- Ciara Linnane
-
Gene Editor Verve Unveils Second Way to Lower Cholesterol
- Barron's Online
-
Beam Gets FDA Nod for First Gene-Editing Trial
- Barron's Online
-
Gene Therapy Is a Huge Opportunity. It Pays to be Patient.
- Barron's Online
-
Verve Therapeutics started at hold with $58 stock price target at Stifel Nicolaus
- Tomi Kilgore
-
Verve started at neutral with $50 stock price target at J.P. Morgan
- Tomi Kilgore
-
Verve Therapeutics shares soar 68% in trading debut
- Ciara Linnane
Other News on VERV
-
Verve Therapeutics: Exciting Science And A Rich Valuation
- Seeking Alpha
-
Verve Therapeutics (VERV) Investor Presentation - Slideshow
- Seeking Alpha
-
ACMR, ARQQ and NXTC among mid-day movers
- Seeking Alpha
-
10-Q: VERVE THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Prime Medicine: CRISPR 3.0 Company
- Seeking Alpha
-
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2022 Update
- Seeking Alpha
-
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
- Seeking Alpha
-
Verve Therapeutics: Cathie Wood Adds To ARKK
- Seeking Alpha
-
Crispr Gene-Editing Drugs Show Promise in Preliminary Study
- The Wall Street Journal Interactive Edition
-
Intellia falls as analysts react to CRISPR readouts
- Seeking Alpha
-
Beam Therapeutics: Now Is Not The Right Time To Own
- Seeking Alpha
-
Why Verve Therapeutics Stock Crushed It This Week
- Motley Fool
- Loading more headlines...
Press Releases on VERV
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com